Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention. Fontana: GINA; 2019.
   Google Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706.
   PubMed Web of Science ®Google Scholar
• Fukutomi Y, Nakamura H, Kobayashi F, et al. Nationwide cross-sectional population-based study on the prevalences of Asthma and Asthma Symptoms among Japanese Adults. Int Arch Allergy Immunol. 2010;153(3):280–287.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Allergology. Japanese guidelines for adult asthma 2017. Allergol Int. 2017;66:163–189.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Allergology. Japanese guidelines for adult asthma 2018. Tokyo: Kyowa kikaku Ltd.; 2018.
   Google Scholar
• Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease. diagnosis of diseases of chronic airflow limitation: asthma copd gina gold. Fontana: GINA and GOLD; 2015.
   Google Scholar
• Yayan J, Rasche K. Asthma and COPD: similarities and differences in the pathophysiology, diagnosis and therapy. Adv Exp Med Biol. 2016;910:31–38.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2016;12:73–83.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Dilleen M, Morris K, et al. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:781–792.
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Reinsch T, et al. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. Respir Med. 2018;142:73–80.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Managament, and Prevention of Chronic Obstructive Pulmonary Disease – 2019 Report. 2019.
   Google Scholar
• Kew KM, Dahri K. Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Syst Rev. 2016;2(1):CD011721.
   Google Scholar
• Ing AJ. Cough and gastro-oesophageal reflux disease. Pulm Pharmacol Ther. 2004;17(6):403–413.
   PubMed Web of Science ®Google Scholar
• Ioachimescu OC, Desai NS. Nonallergic triggers and comorbidities in asthma exacerbations and disease severity. Clin Chest Med. 2019;40(1):71–85.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Nordenstedt H, Nilsson M, Johansson S, et al. The relation between gastroesophageal reflux and respiratory symptoms in a population-based study: the Nord-Trøndelag health survey. CHEST. 2006;129(4):1051–1056.
   PubMed Web of Science ®Google Scholar
• Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–129.
   PubMed Web of Science ®Google Scholar
• Shirai T, Mikamo M, Tsuchiya T, et al. Real-world effect of gastroesophageal reflux disease on cough-related quality of life and disease status in asthma and COPD. Allergol Int. 2015;64(1):79–83.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796.
   PubMed Web of Science ®Google Scholar
• Inoue H, Kozawa M, Milligan KL, et al. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019;29:13.
   PubMed Web of Science ®Google Scholar
• Atsuta R, Takai J, Mukai I, et al. Patients with Asthma prescribed once-daily fluticasone Furoate/Vilanterol or twice-daily fluticasone Propionate/Salmeterol as maintenance treatment: analysis from a Claims Database. Pulm Ther. 2018;4(2):135–147.
   PubMedGoogle Scholar
• Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14(1):25–29.
   PubMed Web of Science ®Google Scholar
• Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma. 2008;45(9):723–729.
   PubMed Web of Science ®Google Scholar
• Latry P, Pinet M, Labat A, et al. Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clin Ther. 2008;30(Spec No):1058–1068.
   PubMed Web of Science ®Google Scholar
• Laforest L, Licaj I, Devouassoux G, et al. Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. Chron Respir Dis. 2013;10(1):11–18.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kamiishi N, Miyata J, et al. Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease. Copd. 2015;12:233–239.
   PubMedGoogle Scholar
• Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care 2014. Available from: https://www.europeanpharmaceuticalreview.com/news/27112/asthma-spiriva-tiotropium-respimat-becomes-lama-licensed-asthma-care/.
   Google Scholar
• Boehringer Ingelheim. SPIRIVA RESPIMAT prescribing information. Germany: Boehringer Ingelheim; 2004.
   Google Scholar
• Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Fontana: GINA; 2019.
   Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938.
   PubMed Web of Science ®Google Scholar
• Northern Ireland Formulary. 3.2b Compound ICS/LABA Preparations – [Asthma] 2018; [cited 2019 Aug 01]. Available from: http://niformulary.hscni.net/Formulary/Adult/3.0/3.2/3.2b/Pages/default.aspx.
   Google Scholar
• Sakamoto H, Rahman M, Nomura S, et al. Japan health system review. New Delhi: World Health Organization. Regional Office for South-East Asia; 2018. 2018. en.
   Google Scholar
• Number of deaths by sex and rate according to the year-by-year classification of cause of death [Internet]. 2017; [cited 2019 Aug 02]. Available from: https://www.e-stat.go.jp/dbview?sid=0003214720.
   Google Scholar